None listed
Conditions
Brief summary
The QoVax SET research pilot study is designed to investigate intrinsic and extrinsic host and viral determinants of vaccine safety, immunity and efficacy in Queensland. Specifically, the QoVax SET Program seeks to determine whether the vaccines administered by Queensland Health facilities are safe and effective in the Queensland community to; • Induce SARS-CoV2 immunity, • Limit the severity of virus-induced disease, and • Sustain immunity and protection from SARS-CoV2 disease in QLD.
Interventions
COVID-19 vaccines: BNT162b2 (BioNTech, Pfizer) or ChAdOx1 (Oxford, AstraZeneca)
Participants will be recruited prior to the first dose of vaccine. A participant completed questionnaire and blood and saliva samples are collected prior to vaccination. The survey and blood and saliva specimens are repeated just prior to the second dose of vaccine and then at 4 weeks, 6 months and 12 months post the second dose of vaccine.
Sponsors
Metro North Hospital and Health Service
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
People over 18 years of age who: a) are eligible for the Queensland Health (QH) COVID vaccine program b) register to receive the vaccine at participating QH sites
Exclusion criteria
a) Not resident in Queensland b) Unable or decline to give informed consent c) Have a contraindication to venepuncture d) do not speak/read English well enough to understand the participant information form and complete the surveys
Outcome results
None listed